Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Ozempic-Like Drugs Could Have a Surprising Effect on Alcohol Cravings : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-30

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 7Not checkedA review published in Biological Psychiatry brings together evidence suggesting Ozempic-like GLP-1 drugs could help people with alcohol use disorder.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 7Not checkedThe article concludes that semaglutide may help some people drink less heavily, but whether it reliably reduces craving and for whom remains uncertain.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 7Not checkedIn one randomized trial of 127 people with alcohol use disorder, exenatide did not significantly reduce heavy drinking days overall compared with placebo, though an exploratory analysis suggested possible benefit in participants with obesity and brain scans showed a weaker response to alcohol-related images in reward-related regions.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 7Not checkedIn a separate study of 48 people with alcohol use disorder who were not seeking treatment, semaglutide led to less drinking in a laboratory test, fewer drinks on drinking days, and lower weekly craving, but did not significantly change drinking frequency or average drinks per calendar day.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 7Not checkedThe strongest published evidence described in the article comes from a 26-week trial in people with obesity and moderate-to-severe alcohol use disorder, where semaglutide reduced heavy drinking days more than placebo and also reduced overall alcohol intake.View evidenceHide evidence

As stated41.1-percentage-point reduction from baseline vs 26.4 points with placebo; treatment difference 13.7 percentage points

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 7Not checkedA newer randomized oral semaglutide trial reportedly found fewer heavy drinking days, but its primary cue-triggered craving measure did not differ significantly from placebo, while a daily-life craving measure improved.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 7Not checkedThe article says health record studies have linked GLP-1 prescriptions to fewer alcohol-related events, but these studies cannot prove the medications caused the change.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 17 candidate papers

CandidateOpen access

GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.

Biological Psychiatry Global Open Science · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

The Use of GLP-1 Agonists in Alcohol Use Disorder and Reducing Alcohol Consumption: A Scoping Review

Research Posters · 2025 · Crossref

Source (opens in a new tab)

And 11 more candidates considered.